Posts Tagged ‘Combination Immune Checkpoint Blockade’

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Posted by • November 2nd, 2016

Oncologists and patients with cancer eagerly await new therapies that efficiently target cancer and avoid damage to normal tissues. In 2015, a randomised controlled trial investigated the role of two immune checkpoint inhibitors: ipilimumab — an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody — and nivolumab — an anti-programmed death-1 (PD-1) antibody. Patients with untreated metastatic… Read More…